IRVINE, Calif.–(BUSINESS WIRE)–Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical
technology company focused on the development and commercialization of
novel implantable Sacral Neuromodulation (“SNM”) devices for the
treatment of urinary
and bowel dysfunction, today announced that it will release
financial results for the 2018 fourth quarter and full year after the
market closes on Tuesday, March 5, 2019.
In conjunction with the release, the Company will host a conference call
with the investment community that same day at 4:30 p.m. Eastern Time to
discuss the financial results and recent business developments.
Interested parties may access the live call via telephone by dialing
(866) 687-5771 (U.S.) or (409) 217-8725 (International) and using
A live webcast of the call may be accessed by visiting the Events &
Presentations page of the investors section of the Company’s website at ir.axonicsmodulation.com.
A replay of the webcast will be available shortly after the conclusion
of the call and will be archived on the Company’s website for 90 days.
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, is focused on development and
commercialization of a novel implantable SNM system for patients with
urinary and bowel dysfunction. The Axonics r-SNM® System is
the first rechargeable Sacral Neuromodulation system approved for sale
in Europe, Canada and Australia. Premarket approval for the r-SNM System
is currently pending with the U.S. Food & Drug Administration. For more
information, visit the Company’s website at www.axonicsmodulation.com.
Axonics Modulation Technologies, Inc.
President & Chief Financial Officer
Investor & Media Contact